Needham Maintains Buy on NeoGenomics, Raises Price Target to $19

Benzinga Newsdesk www.benzinga.com Positive 72.0%

Neg 0% Neu 0% Pos 72%

Needham analyst Mike Matson maintains NeoGenomics (NASDAQ:NEO) with a Buy and raises the price target from $15 to $19.

Comments

No comments yet. Be the first!